RCUS — Arcus Biosciences, Inc.

Summary of Arcus Biosciences, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: Recognized GAAP revenue of $17 million for Q1 2026, primarily from collaboration agreements. Full-year revenue guidance remains at $50 million to $65 million.
• Expenses: R&D expenses totaled $122 million, including nonrecurring workforce costs. G&A expenses were $29 million, with total non-cash stock-based compensation at $19 million.
• Cash Position: Ended the quarter with $876 million in cash, providing a runway until at least 2028. Expected to end 2026 with approximately $600 million in cash due to reduced spending.

2. Strategic Updates and Business Highlights:

• Cascadifan Development: The lead program, cascadifan, is in a Phase 3 kidney cancer study (PEEK-1) with rapid enrollment expected to complete by year-end 2026. The company aims to establish cascadifan as a standard treatment in clear cell renal cell carcinoma (ccRCC).
• Market Opportunity: Cascadifan has a potential market opportunity exceeding $5 billion in ccRCC, with strategies to penetrate both second-line and frontline settings.
• Clinical Data: Promising efficacy data presented, including a 45% overall response rate (ORR) in late-line cohorts and a median progression-free survival (PFS) of 15.1 months, significantly outperforming competitor belzutafan.
• Pipeline Expansion: Ongoing development in inflammation and immunology, with AB-102 expected to enter the clinic in 2026, alongside other candidates targeting rheumatoid arthritis and psoriasis.

3. Forward Guidance and Outlook:

• Clinical Milestones: Multiple data readouts anticipated in 2026, including initial data from cascadifan combinations and updates from late-line monotherapy cohorts.
• Spending Strategy: Focused on cascadifan development, with a significant reduction in overall R&D expenses expected in 2026 and 2027 due to streamlined operations and reduced headcount.

4. Bad News, Challenges, or Points of Concern:

• Discontinued Trials: The Phase 3 STAR-121 study for domvanalimab was discontinued due to futility, highlighting challenges in the competitive landscape.
• Market Competition: Concerns regarding the competitive pressures from established therapies, particularly TKIs and the implications of recent failures in similar trials (e.g., Merck’s LITESPARK-012).
• Regulatory and Safety Risks: The need to demonstrate safety and efficacy in combination therapies, particularly in light of recent failures in triplet regimens, poses a risk to the development strategy.

5. Notable Q&A Insights:

• Cascadifan vs. Competitors: Management expressed confidence in cascadifan’s superior pharmacodynamic profile compared to belzutafan, particularly regarding durability of response and treatment tolerability.
• Frontline Strategy: Discussions emphasized a preference for a TKI-sparing regimen in frontline settings, with ongoing evaluations of patient selection and combination strategies.
• Adjuvant Setting Considerations: The company is prioritizing first, second, and third-line settings over adjuvant therapy due to perceived lower market potential and physician hesitance to add therapies in that context.
• Clinical Data Expectations: Initial data from the triplet cohort (cascadifan, ipi, and anti–PD-1) is expected in the fall, focusing on safety and primary progression rates to inform future Phase 3 trials.

Overall, Arcus Biosciences is positioned for significant developments in 2026, particularly with cascadifan, while navigating competitive and regulatory challenges in the oncology landscape.